Glutamate-based Therapies for Psychiatric Disorders
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the t...
محفوظ في:
| مؤلف مشترك: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | الكتروني كتاب الكتروني |
| اللغة: | English |
| منشور في: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2010.
|
| الطبعة: | 1st ed. 2010. |
| سلاسل: | Milestones in Drug Therapy,
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1007/978-3-0346-0241-9 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
جدول المحتويات:
- N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
- Ionic Glutamate Modulators in Depression (Zinc, Magnesium)
- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy
- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors
- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders
- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia
- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia
- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence
- Metabotropic Approaches to Anxiety.